



NEWS RELEASE

CareDx Presents New Data at the American Society for Histocompatibility and Immunogenetics Annual Meeting

2023-10-17

Demonstrates Breadth of Offerings for HLA Laboratories and Validation of AlloSeq HCT

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced a leading presence at the 49th annual meeting of the American Society for Histocompatibility and Immunogenetics (ASHI) being held in San Antonio, Texas from October 16-20, 2023.

The latest advances across CareDx’s portfolio of HLA typing solutions and AlloSeq HCT for use in hematopoietic stem cell monitoring¹ are being showcased across nineteen abstracts and two company-sponsored symposia. These peer-reviewed abstracts demonstrate the scientific validation and utility of CareDx products and solutions.

“CareDx is proud to be a leading sponsor of this year’s ASHI meeting and driving continued innovation in transplantation with our best-in-class portfolio of HLA typing and workflow solutions,” said Reg Seeto, CEO and President of CareDx. “We are also excited to share the latest update on AlloSeq HCT, a transformative solution for chimerism monitoring in patients undergoing hematopoietic stem cell transplantation.”¹

For HLA laboratories, CareDx offers NGS-based typing solutions with AlloSeq Tx,¹ QTYPE,¹ SSP, and mTilda LIMS (Laboratory Information Management System). AlloSeq Tx¹ delivers a novel method for matching transplant recipients and potential donors. The hybrid capture approach to matching is unique to CareDx and gives labs flexibility in gene content and increased robustness over other methodologies. mTilda LIMS software, virtual



crossmatch, and epitope analysis are designed to improve transplant outcomes. For allogeneic hematopoietic stem cell transplant (allo-HCT) monitoring, AlloSeq HCT¹ offers a streamlined and sensitive approach for NGS-based engraftment monitoring and surveillance following allo-HCT.

CareDx will host two symposia focused on “Innovation Across the Pre- and Post-Transplant Journey”:

Tuesday, October 17, moderated by Hal Gibson, Senior Vice President, Strategic Partnering, CareDx:

- The History of Donor-Derived cfDNA in Transplantation. Robert Woodward, PhD, Chief Scientific Officer, CareDx.
- Evolving Clinical Utility of Donor-Derived Cell-DNA for Post-Transplant Management. Gaurav Gupta, MD, Professor of Medicine and Surgery, Interim Chief, VCU Division of Nephrology, Medical Director of Kidney/Pancreas Transplantation, Hume-Lee Transplant Center.
- Elevating the Standard of Care in Transplant Surveillance: Integrating Non-Invasive Biomarkers with Clinical Parameters. Carmen Lefaucheur, MD, Head of the Department of Nephrology and Kidney Transplantation, Saint-Louis Hospital-APHP, Paris, France, and Professor of Nephrology at Université Paris Cité, Medical Director of the Paris Institute for Transplantation & Organ Regeneration, Director of the Research FHU Apollo.

Wednesday, October 18, moderated by Curtis Lind, Vice President, Head of R&D, Products, CareDx, and Michael Reardon, Senior Director, HLA Software Portfolio, CareDx:

- Latest Advances in AlloSeq Products & Software. Beata Kmiec, PhD, Product Manager, CareDx.
- Revolutionizing Chimerism Analysis: Harnessing the Power of NGS and SNP Panels for Superior Results. Ahmed Mostafa, MD, PhD, Director, Technical Supervisor, and Clinical Consultant, Histocompatibility and Immunogenetics Laboratory, St. Paul's Hospital—Saskatoon.
- Virtual Crossmatching and Epitope Analysis as Informational Aids in the Transplant Decision Making Process: A Review of VXMatch and VECTR. Eszter Lazar-Molnar, PhD, D(ABMLI), F(ACHI), Assistant Professor Department of Pathology, University of Utah.

About CareDx – The Transplant Company

CareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.

Forward Looking Statements

This press release includes forward-looking statements related to CareDx, Inc., including statements regarding the potential benefits and results that may be achieved with CareDx's leading presence and sponsorship in 2023 ASHI meeting (the "Meeting"), AlloSeq HCT and its HLA typing solutions, and its presentation of the latest data on AlloSeq HCT and HLA typing solutions at the Meeting (the "Presentation"). These forward-looking statements are based upon information that is currently available to CareDx and its current expectations, speak only as of the date hereof, and are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including risks that CareDx does not realize the expected benefits of its leading presence and sponsorship in the Meeting, AlloSeq HCT or its HLA typing solutions, or its Presentation; general economic and market factors; and other risks discussed in CareDx's filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2022 filed by CareDx with the SEC on February 27, 2023, the quarterly report on Form 10-Q for the quarter ended March 31, 2023 filed by CareDx with the SEC on May 10, 2023, the quarterly report on Form 10-Q for the quarter ended June 30, 2023 filed by CareDx with the SEC on August 8, 2023, and other reports that CareDx has filed with the SEC. Any of these may cause CareDx's actual results, performance, or achievements to differ materially and adversely from those anticipated or implied by CareDx's forward-looking statements. CareDx expressly disclaims any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.

References

1. AlloSeq Tx17, AlloSeq HCT, and QTYPE are for research use only in the United States.

CareDx, Inc.

Media Relations

Anna Czene

818-731-2203

[aczene@caredx.com](mailto:aczene@ caredx.com)

Investor Relations

Greg Chodaczek

Investor@caredx.com

Source: CareDx, Inc.